
Lung Cancer: Advances in Current Treatment Modalities and Patient Classification
Tuesday, March 25, 2014
Presented By
Lung cancer is one of the most common and deadliest cancers worldwide. The majority of patients present with advanced disease and despite decades of work, overall survival rates are still very low. Recent advances in treatment modalities have increased the risk/benefit ratio for these patients and this may translate into increased survival rates. A better understanding of the genetic heterogeneity of lung cancer has led to a new patient classification scheme that may help inform on patient selection for future trials. The topics to be discussed in this symposium include: lung cancer classification, common mutations and insights for patient selection, the use of intraoperative chemotherapy and minimally invasive surgery to treat thoracic cancers, and a discussion on insights from clinical trials using targeted and combination chemotherapy for small cell and non-small cell lung cancers.
Reception to follow.
This event will also be broadcast as a webinar.
Please note: Transmission of presentations via the webinar is subject to individual consent by the speakers. Therefore, we cannot guarantee that every speaker's presentation will be broadcast in full via the webinar. To access all speakers' presentations in full, we invite you to attend the live event in New York City when possible.
Registration and Webinar Pricing
Member | $0 |
Student/Postdoc Member | $0 |
Nonmember | $40 |
Nonmember (Student / Postdoc / Resident / Fellow) | $20 |
The Biochemical Pharmacology Discussion Group is proudly supported by
Mission Partner support for the Frontiers of Science program provided by 
Agenda
* Presentation titles and times are subject to change.
March 25, 2014 | |
11:30 AM | Registration |
12:00 PM | Welcome and Introduction |
12:10 PM | Evolving Therapies for Early Stage Non-Small Cell Lung Cancer |
12:50 PM | Personalized Therapy for Advanced Non Small Lung Cancer: From the Battle Trial to Master Protocols |
1:30 PM | EGFR-mutated Lung Cancer: A Paradigm of Molecular Oncology |
2:10 PM | Coffee break |
2:40 PM | Promising New Agents on the Horizon for NSCLC |
3:20 PM | Antibody-mediated Inhibition of Phosphatidylserine: A Novel Strategy for Immune Checkpoint Blockade |
4:00 PM | Closing Remarks Networking Reception |
5:00 PM | Close |
Speakers
Organizers
Magdalena Alonso-Galicia, PhD
Forest Research Institute
Magdalena Alonso-Galicia, PhD, is a Senior Principal Scientist at the Forest Research Institute, a subsidiary of Forest Laboratories, Inc. in Jersey City, NJ. As a non-clinical pharmacologist, she is responsible for developing and directing pharmacology studies to support approved products and early & late-stage drug candidates in the respiratory and cardiovascular therapeutic areas. She is also the pharmacology reviewer of new licensing opportunities in multiple therapeutic areas such as cardiovascular, respiratory, renal and metabolic disorders. Prior to joining Forest in 2010, she worked in drug discovery at Boehringer Ingelheim and Merck & Co., Inc. in the areas of hypertension, heart failure and chronic kidney diseases. She holds a PhD in Physiology & Biophysics from the University of Mississippi and underwent post-doctoral training at the Medical College of Wisconsin.
Shashidhar S. Jatiani , PhD
Forest Research Institute
Dr. Shashidhar S Jatiani has worked in preclinical anticancer drug discovery and development since 2005. He obtained his Ph.D. in Molecular from Tata Institute for Fundamental Research, Mumbai, India. He currently works as a research scientist in the pharmacology group of Forest Research Institute. Dr. Jatiani has extensive preclinical experience in myeloproliferative neoplasms, leukemias, solid tumors and immuno-oncology.
Huiping Jiang, PhD
Boehringer-Ingelheim Pharmaceuticals
Dr. Huiping Jiang has a bachelor’s degree in biochemistry and a Ph.D. in molecular cell biology. Her postdoctoral research focus was in mammalian genetics and cellular signal transduction. Huiping started her pharmaceutical career at AstraZeneca as a research scientist and then principal scientist at Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) specializing in transgenic pharmacological models. Huiping’s current position is director, regulatory affairs at BIPI. Huiping has been an active steering committee member of BPDG and has contributed to multiple successful NYAS symposiums.
George Zavoico, PhD
HC Wainwright
George B. Zavoico, Ph.D., joined H.C. Wainwright & Co. (HCW), a boutique investment bank and institutional broker-dealer, as Managing Director and Senior Equity Analyst in early 2014. He has over 10 years of experience as a life sciences equity analyst writing research on publicly traded equities. Before joining HCW, Dr. Zavoico was Managing Director and Senior Equity Analyst at MLV & Co., and an Equity Analyst at Westport Capital Markets and Cantor Fitzgerald. Before becoming an equity analyst, Dr. Zavoico established his own consulting company serving the biotech and pharmaceutical industries by providing competitive intelligence and marketing research, due diligence services, and guidance in regulatory affairs. He also wrote extensively on healthcare and the biotech and pharmaceutical industries for periodicals targeting the general public and industry executives. Dr. Zavoico began his career as a Senior Research Scientist at Bristol-Myers Squibb Co., moving on to management positions at Alexion Pharmaceuticals, Inc. and T Cell Sciences, Inc. (now Celldex Therapeutics, Inc.). He has a B.S. in Biology from St. Lawrence University and a Ph.D. in Physiology from the University of Virginia. He held post-doctoral fellowships at the University of Connecticut School of Medicine and at Harvard Medical School/Brigham & Women's Hospital. He has published over 30 papers in peer-reviewed journals and has co-authored four book chapters.
Jennifer Henry, PhD
The New York Academy of Sciences
Speakers
Rolf Brekken, PhD
UT Southwestern
Dr. Brekken grew up in Grapevine, TX, received his BA in Biology from Luther College in Decorah, IA and his PhD (Cell and Molecular Biology) from UT Southwestern Medical Center where he trained under Dr. Philip Thorpe. His graduate studies were focused on developing novel therapies that target the vascular compartment of tumors. He was a postdoctoral fellow in the Department of Vascular Biology at the Hope Heart Institute in Seattle, WA where he studied how the extracellular matrix contributes to vascular function and tumor progression. He joined the Department of Surgery at UT Southwestern as faculty in 2002 and was promoted to Associate Professor with tenure in 2009. His laboratory is located in the Hamon Center for Therapeutic Oncology Research and he is also a member of the Simmons Comprehensive Cancer Center at UT Southwestern. In broad terms Dr. Brekken’s laboratory studies the tumor microenvironment. His group is interested in how therapy affects the tumor microenvironment and how stromal elements influence response to therapy. Current studies in the laboratory focus on: the function of matricellular proteins (SPARC and fibulin-5) in cancer; the biology of anti-VEGF therapy; the contribution of macrophages and other immune cells to the metastatic cascade; and phosphatidylserine-mediated immune suppression in tumors. Dr. Brekken is the Effie Marie Cain Scholar in Angiogenesis Research and receives funding from the ACS, NCI, DOD, CPRIT, Mary Kay Foundation and biopharmaceutical companies. He is an author on over 100 peer-reviewed scientific papers and is a senior editor for Cancer Research.
Jessica S. Donington, MD
NYU Langone Medical Center
Dr. Jessica Donington is a General Thoracic Surgeon at NYU School of Medicine. She is an associate professor in the Department of Cardiothoracic Surgery, the director of the NYU Thoracic Oncology Translational Laboratory and chief of the Thoracic Surgery Service at Bellevue Hospital. Her laboratory work focuses on the discovery and validation of diagnostic and prognostic biomarkers for thoracic malignancies and on the role of osteopontin, a ubiquitous protein, in carcinogenesis. Her clinical and interests focus on the diagnosis and treatment of mesothelioma and non-small cell lung cancer. Areas of clinical expertise include the use of multimodality therapy for thoracic malignancies, treatment options for high risk patients with early stage lung cancer and cancer in women.
Balazs Halmos, MD
Columbia University Medical Center
Balazs Halmos is an Associate Professor of Medicine at Columbia University and Section Chief of Thoracic Oncology at New York Presbyterian Hospital- Columbia. Besides maintaining an active clinical practice focused on the management of patients with malignancies of the thoracic cavity, Dr. Halmos oversees the thoracic clinical trials program at Columbia. He also runs a translational research laboratory investigating novel ways of overcoming resistance to conventional as well as targeted therapeutics. In addition, he is Chair of the Cancer IRB of Columbia University.
Roy S. Herbst, MD, PhD
Yale School of Medicine
Dr. Roy S. Herbst is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program, and Associate Director for Translational Research at Yale Comprehensive Cancer Center and Yale School of Medicine in New Haven, CT. Dr. Herbst has led the Phase I development of several of the new generation of targeted agents for NSCLC, including gefitinib, erlotinib, cetuximab, and bevacizumab. He is co-lead for the BATTLE-1 effort, co-leads the subsequent BATTLE-2 clinical trial program, and serves as a Co-Program Leader of the Developmental Therapeutics Program for the YCC Cancer Center Support Grant (CCSG). He is a member of the National Cancer Policy Forum for which he has organized an IOM meeting focused on policy issues in personalized medicine. His laboratory work is focused on angiogenesis and dual EGFR/VEGFR inhibition in NSCLC. Previously, Dr. Herbst served as the Barnhart Distinguished Professor and Chief of the Section of Thoracic Medical Oncology in the Department of Thoracic/Head and Neck Medical Oncology, at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. He also served as Professor in the Department of Cancer Biology and Co-Director of the Phase I Program. Dr. Herbst is author or co-author of more than 250 publications, including peer-reviewed journal articles, abstracts, and book chapters. He has contributed his work to many prominent journals, such as Journal of Clinical Oncology, Clinical Cancer Research, Lancet, and the New England Journal of Medicine. Dr. Herbst is an active member of ASCO, AACR, IASLC (International Association for the Study of Lung Cancer), RTOG (Radiation Therapy Oncology Group), and SWOG (Southwest Oncology Group Lung Committee).
Suresh S. Ramalingam, MD
Emory University
Dr. Suresh Ramalingam received his medical degree at Kilpauk Medical College, Madras, India. He completed his residency in Internal Medicine at Wayne State University, Detroit, MI, where he also served as a Chief Medical Resident. He then completed a fellowship in Hematology and Medical Oncology at the University of Pittsburgh Medical Center, Pittsburgh, PA. He is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology and is an active member of American Society of Clinical Oncology, the American Association for Cancer Research, and the International Association of Lung Cancer Study. Dr. Ramalingam plays an active role in the ECOG-ACRIN Cancer Research Group as the Chair of the Thoracic Malignancies Committee. He also serves on the editorial board of leading cancer journals such as Journal of Clinical Oncology, Cancer, Clinical Lung Cancer and Cancer, Chemotherapy and Pharmacology. Dr. Ramalingam is the recipient of several awards, including the ‘James Eckman Award for Excellence in Teaching’, Department of Hematology and Medical Oncology, Emory University, and the Distinguished Cancer Scholar Award, Georgia Cancer Coalition. In addition, he is also a recipient of the ‘ASCO Career Development Award’ (2006-09). Dr. Ramalingam serves on several international, national and Institutional Committees.
Sponsors
Academy Friend
Peregrine Pharmaceuticals, Inc.
Grant Support
This program is supported in part by a grant from Genentech Inc.
Promotional Partners
The International Association for the Study of Lung Cancer
North Jersey Section American Chemical Society
The Biochemical Pharmacology Discussion Group is proudly supported by
Mission Partner support for the Frontiers of Science program provided by 
Abstracts
Evolving Therapies for Early Stage Non-Small Cell Lung Cancer
Jessica S. Donington, NYU Langone Medical Center
Personalized Therapy for Advanced Non Small Lung Cancer: From the Battle Trial to Master Protocols
Roy S. Herbst, Yale School of Medicine
EGFR-mutated Lung Cancer: A Paradigm of Molecular Oncology
Balazs Halmos, Columbia University Medical Center
Promising New Agents on the Horizon for NSCLC
Suresh S. Ramalingam, Emory University
Antibody-mediated Inhibition of Phosphatidylserine: A Novel Strategy for Immune Checkpoint Blockade
Rolf Brekken, UT Southwestern
Travel & Lodging
Our Location
The New York Academy of Sciences
7 World Trade Center
250 Greenwich Street, 40th floor
New York, NY 10007-2157
212.298.8600
Hotels Near 7 World Trade Center
Recommended partner hotel
Club Quarters, World Trade Center
140 Washington Street
New York, NY 10006
Phone: 212.577.1133
The New York Academy of Sciences is a member of the Club Quarters network, which offers significant savings on hotel reservations to member organizations. Located opposite Memorial Plaza on the south side of the World Trade Center, Club Quarters, World Trade Center is just a short walk to the Academy.
Use Club Quarters Reservation Password NYAS to reserve your discounted accommodations online.
Other nearby hotels
212.945.0100 | |
212.693.2001 | |
212.385.4900 | |
212.269.6400 | |
212.742.0003 | |
212.232.7700 | |
212.747.1500 | |
212.344.0800 |